News and Trends 27 Nov 2018 Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls. Wellington Partners and HBM Healthcare Investments, who specialize in investing in life science companies, joined existing shareholders to lead the fundraising round. Sepsis and resulting […] November 27, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2018 Mastering the Competitive World of Immuno-oncology In recent years the oncology world has focused on using the immune system to target cancer, with CAR-T cell therapy and other success stories revolutionizing the field. Ulf Grawunder, CEO and founder of NBE Therapeutics, a company using antibody drug conjugates to target cancer, discussed how to navigate the competitive area of immuno-oncology at our […] October 25, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2018 Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur What does it take to be a successful biotech entrepreneur? I put this and other similar questions to Dinko Valerio, a highly experienced Dutch geneticist turned serial entrepreneur and investor. While there are many great scientists, it takes a certain something to be able to cross over into industry and build a profitable business. Dinko […] October 23, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 10 Oct 2018 How to Make Industrial Biotech Pay Making enough money to survive long enough to get a product to market can be tough for any biotech, but even more so for companies operating in the industrial space, where it can be less easy to predict development time and potential financial returns. At our recent Refresh event in Paris, Emmanuel Petiot, CEO of […] October 10, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 9 Oct 2018 How to Capitalize on Opportunities in Underserved Disease Areas Developing treatments for underserved diseases can be surprisingly profitable for biotechs, we asked the experts to tell us more about how best to exploit these areas. We hear a lot about cancer therapies or drugs to target heart disease in the press, but overall a lot less about treatments for more underserved areas. Often successful […] October 9, 2018 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2018 Novozymes Releases Enzyme That Helps Chickens Better Absorb Food Novozymes has released a new enzyme that breaks down bacterial cell debris in the gut and allows chickens to absorb more nutrients from their food. The Danish industrial biotech giant partnered with the Dutch health and nutrition company DSM to produce the bacterial muramidase enzyme solution, which is called ‘Balancius’. It has an interesting story […] September 14, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Cambridge Biotech Targets Artificial Pancreas Market With Fast Insulin and Stable Glucagon UK biotech Arecor has raised €6.7M to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The speed of action of insulin has been a limiting factor for development of the artificial pancreas — a combined insulin pump and glucose monitor that would allow real-time control of blood […] September 10, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 More Brexit Bad News: EMA Pulls Contracts Early From UK Regulatory Body The European Medicines Agency (EMA) has pulled all contracts with the UK’s medical regulation body ahead of the UK withdrawing from the EU next year. Until 2018, the EMA has relied on the UK Medicines & Healthcare products Regulatory Agency (MHRA) to assess 20–30% of its drugs on a contract basis, work worth approximately €15.6M […] September 6, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2018 Cassava Plants Gene Edited Using CRISPR to Produce Waxy Starch A team of European researchers applied CRISPR-Cas9 gene editing technology to engineer cassava plants that produce a modified type of starch, in demand for both cooking and industrial processing. The team also managed to speed up the flowering of the plants by introduction of a gene from Arabidopsis plants, which they hope will allow more […] September 5, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2018 Vertex Partners Oxford Genome Analysis Firm To Develop New Personalized Therapies Genomics, a company using machine learning to analyze genetic data, is partnering with precision medicine specialists Vertex Pharmaceuticals to develop new therapies in a 3-year collaboration. The agreement marks the closing of the Oxford-based company’s €28M (£25M) series B fundraising round, as Vertex has also invested €11.7M (£10.5M) in Genomics. If the collaboration is successful […] August 31, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2018 First RNAi Drug Approved in Europe After 20 Years of Research The first ever RNA interference (RNAi) drug, used to treat polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis, has been given marketing approval by the European Commision. The approval follows that of the US FDA who gave the green light to US biotech Alnylam Pharmaceutical’s Onpattro (patisiran) earlier this month following positive Phase III findings in […] August 30, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2018 Women’s Health Biotech Raises €28M to Fund Phase II Menopause Drug Trial UK-biotech KaNDy Therapeutics closed a £25M (€28M) series C round to help finance the upcoming Phase IIb trial of its lead candidate for treating symptoms of the menopause. Unlike other therapies aimed at treating the same symptoms, KaNDy’s drug (NT-814) is not based on hormone replacement therapy, which can take a long time to be […] August 29, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email